<![CDATA[CARTITUDE-2 Cohort A Follow-Up Data and Preparing Patients for CAR TCell Therapy]]>

Summary

Article discusses ciltacabtagene autoleucel (ciltacel), a BCMA-directed CAR T-cell therapy approved for relapsed or refractory multiple myeloma, in the context of CARTITUDE-2 Cohort A follow-up data presentation and patient preparation for CAR T-cell therapy.